"No Treatments or Vaccines: Bundibugyo Ebola Strikes Health Care Void in Central Africa"

Compounded by Conflict Zones and Poor Medical Infrastructure, Case Tracking Proves Difficult
Rapid Spread in DRC and Uganda, Yet Response Remains Slow

The death toll from the Ebola virus disease outbreak in eastern Democratic Republic of the Congo (DRC) has surpassed 130. The World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) as the Bundibugyo strain of Ebola spread from the DRC to Uganda, and is now reviewing the potential use of experimental vaccines and treatments.

AP Yonhap News

On May 19 (local time), the Associated Press reported that there were at least 134 suspected deaths and more than 500 suspected cases of Bundibugyo Ebola in eastern DRC. Reuters, citing the DRC health authorities' daily report, stated that there were 131 deaths and 516 suspected cases. Among these, 33 confirmed cases were reported in the DRC, and 2 confirmed cases in neighboring Uganda.

According to the WHO, this outbreak began in the Mongbwalu, Rwampara, and Bunia health zones of the Ituri province in northeastern DRC. The first known suspected case was a healthcare worker who showed symptoms on April 24 and died at a medical facility in Bunia. Subsequent investigations confirmed additional deaths among healthcare workers and clusters of deaths in the community. On May 15, the DRC government officially declared its 17th Ebola outbreak.

Confirmed in Uganda Across the Border

The virus responsible for this outbreak is the Bundibugyo strain of Ebola. The Bundibugyo strain was first identified in the Bundibugyo region of western Uganda in 2007, and during previous outbreaks, fatality rates were reported to be around 30-50%. The WHO explained that, unlike the Zaire strain, there are no approved vaccines or specific treatments for the Bundibugyo strain, and that early fluid administration and electrolyte correction—supportive therapy—are essential for improving survival rates.

The spread has crossed borders and was also confirmed in Uganda. The World Health Organization reported confirmed cases in Uganda's capital, Kampala, on the 15th and 16th, related to patients who moved from the Democratic Republic of the Congo. AP Yonhap News

The spread has crossed borders and was confirmed in Uganda as well. The WHO reported that confirmed cases were identified in Kampala, the capital of Uganda, on the 15th and 16th, related to patients who had traveled from the DRC. Both patients were admitted to intensive care units. The Associated Press, citing Ugandan reports, stated that one of the two confirmed patients had died.

WHO Director-General Tedros Adhanom Ghebreyesus stated, "The scale and speed of this outbreak are deeply concerning." The WHO identified several major risk factors: the outbreak being confirmed in urban areas such as Goma in the DRC and Kampala in Uganda; cases of healthcare worker infections; and large-scale population movements in conflict-affected areas such as Ituri. To facilitate an emergency response, the WHO approved 3.9 million dollars in emergency funding and deployed on-site response teams and supplies.

Meanwhile, the issues of vaccine development and deployment have also emerged as key points of contention. Currently approved Ebola vaccines primarily target the Zaire strain, making them difficult to apply directly to the current Bundibugyo outbreak. Regarding the use of Zaire strain vaccines for this outbreak, a WHO official stated that "experts agree they cannot be used," but also stressed that further research is needed. The WHO and health authorities in each country believe that isolation of suspected cases, contact tracing, infection control in healthcare facilities, and managing community burial practices are all critical to stopping the spread.

However, the possibility of deploying experimental vaccines remains open. The Associated Press, citing a source at the DRC National Institute of Biomedical Research, reported that the DRC is expected to receive supplies of pan-Ebola candidate vaccines currently being developed in the United States and the United Kingdom. These candidate vaccines are said to have been developed by researchers at the University of Oxford, but experts caution that it will take time before mass vaccination is possible.

United States Raises Response Level

Amid the rapid spread, the United States has also raised its response level. On May 18, the U.S. Centers for Disease Control and Prevention (CDC) announced entry restrictions for non-U.S. passport holders who had visited the DRC, Uganda, or South Sudan within the past 21 days. At the same time, the CDC said it would strengthen screening of arrivals in the U.S., traveler monitoring, contact tracing, and laboratory testing capacity. However, the CDC assessed that the immediate risk to the general public in the U.S. remains low.

The issue of vaccine development and deployment has also emerged as a key concern. Currently approved Ebola vaccines primarily target the Zaire strain of Ebola, making it difficult to apply them directly to this Bundibugyo strain outbreak. The Guardian reported that the World Health Organization (WHO) has convened an international expert group to review the potential use of candidate vaccines, treatments, and diagnostic methods. AP Yonhap News

On the same day, the U.S. State Department temporarily suspended all visa operations at U.S. embassies in Juba, South Sudan; Kinshasa, DRC; and Kampala, Uganda. The suspension applies to all non-immigrant visas—including tourist, business, student, and exchange visas—as well as immigrant visas. Cases of Americans infected with Ebola have also been confirmed. CBS News reported that an American doctor conducting medical missionary work in the DRC tested positive for Ebola and was transferred to Germany for treatment. Previously, CBS reported that at least six Americans had been exposed to Ebola in the DRC. Reuters reported that the confirmed American patient and six high-risk contacts would be transferred to Europe for isolation and observation.

The Africa Centres for Disease Control and Prevention (Africa CDC) expressed concern over the broad travel restrictions imposed by the United States. Africa CDC pointed out that general travel bans and border closures fuel fear, harm the economy, and hinder humanitarian and health activities. Instead, it emphasized the importance of surveillance at the outbreak sites, laboratory diagnostics, contact tracing, infection prevention, safe burial procedures, and international financial support. International health experts warn that the actual scale of the damage may be greater than official figures suggest. The Guardian, citing a relief organization official, reported that the currently identified cases "may be just the tip of the iceberg." With ongoing conflict, poor medical infrastructure, shortages of protective equipment, and delayed diagnoses, some predict it could take several months to contain the outbreak.

This content was produced with the assistance of AI translation services.